1. Home
  2. VIPS vs PTGX Comparison

VIPS vs PTGX Comparison

Compare VIPS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vipshop Holdings Limited

VIPS

Vipshop Holdings Limited

HOLD

Current Price

$14.38

Market Cap

7.7B

ML Signal

HOLD

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

HOLD

Current Price

$101.96

Market Cap

6.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIPS
PTGX
Founded
2008
2006
Country
China
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
6.4B
IPO Year
2012
2016

Fundamental Metrics

Financial Performance
Metric
VIPS
PTGX
Price
$14.38
$101.96
Analyst Decision
Buy
Strong Buy
Analyst Count
4
13
Target Price
$19.58
$108.23
AVG Volume (30 Days)
2.2M
430.0K
Earning Date
05-19-2026
05-07-2026
Dividend Yield
4.38%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
N/A
N/A
Revenue This Year
$3.79
$874.25
Revenue Next Year
$2.05
N/A
P/E Ratio
$9.00
$2,040.80
Revenue Growth
N/A
N/A
52 Week Low
$13.36
$46.16
52 Week High
$21.08
$107.84

Technical Indicators

Market Signals
Indicator
VIPS
PTGX
Relative Strength Index (RSI) 46.73 51.92
Support Level $14.08 $96.36
Resistance Level $15.23 $106.85
Average True Range (ATR) 0.48 4.14
MACD 0.06 -0.12
Stochastic Oscillator 45.34 59.51

Price Performance

Historical Comparison
VIPS
PTGX

About VIPS Vipshop Holdings Limited

Vipshop is a leading Chinese online discount retailer offering branded products at attractive discounts of 10%-90% off their original price through daily flash sales. It operates warehousing, retailing, product procurement, software development, and information technology support in-house while outsourcing to third-party logistics providers for distribution and shipments. Branded products on Vipshop's platform are sourced mostly through a consignment model with global brand partners. As of March 31, 2025, Eric Ya Shen, chair and CEO, had 64.5% voting rights. Leading Chinese social media firm and strategic shareholder Tencent also holds a 12.5% interest.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: